Any CML patient that does have a BCR-ABL over 1% and/or Ph* chromosome over 1% after 12 months of TKI usage (particularly nilotinib and dasatinib) may be accepted as a failed case and the treatment strategy may be changed. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.